Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Cadonilimab (AK104) combined with chemotherapy and bevacizumab

"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles):~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period:~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."

Trial Locations (1)

Unknown

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

Caigang Liu

OTHER